(Total Views: 917)
Posted On: 07/23/2022 3:55:47 AM
Post# of 156963
Re: chazzledazzle #126788
Hear me out. Chris Sandburg articles usually aren’t always accurate. I’ve been reading them for the past few years like many others, and although I like them I’m with you on this Chazz. Fuzzy to say the least… I do not think he knows more than most investors do.
I’m not sure where 10 keeps coming from, maybe he has a ton of shares like some and 10 will easily make him a multi millionaire and he just wants to play it safe and cash out. Don’t blame that mindset for many.
The company has had a bumpy road and a lot of mistakes were made along the way which makes 10 sound like a dream to some at this point. A lot was self inflicted but other mistakes were legitimately road blocks from the FDA and possibly BP. If you think it was all self inflicted or not it doesn’t matter the truth is things went slower than anticipated and covid fell flat.
However, it wasn’t too long ago when we were trading at 10 and people where talking about only selling some at 50 and riding the rest for triple digits. Yes triple digits. That’s actually not that unrealistic if we make it and see several approvals over the next 5-10 years.
So when I hear 10 dollars it makes me think of a few things. First people have their individual financial reasons to sell and they change often with time. I won’t get into that but pretty straight forward.
The second thing is, I believe it’s possible that whoever is interested in buying us, if that’s the case, would greatly benefit convincing share holders to sell at 10.
Right ? Because that would be the equivalent of buying something that was 99 precent on sale. So yes I’d be campaigning for 10 all day.
I know nobody asked but since we are on the subject…. I don’t have a single share for sale right now for 10 dollars. Now that doesn’t mean I won’t sell a single share on the way up at 10 this time. If anything it would only be a few thousand shares to say I didn’t miss out like last time and also finally pocket some cash. It would also be the financially smart thing for me to do. That’s why they call it individual financials . Everyone’s different.
So yes 10 imo is a joke. This is also why I do not see a buyout coming. We are too expensive already. Who’s going to pay say 30 billion for a stock that’s trading with a 800 million dollar market cap ? I mean it’s possible but I don’t see it ? Prove me wrong and offer us 50 then we can talk but I don’t see it.
Way too many possible indications. This isn’t a one trick show. The share price could actually be well over 100 dollars in 10 years yet people want to sell at 10?! What ?!
This is why I believe a partner would be best or maybe some other share for share swap so we can watch Leronlimab grow. We have very loyal share holders that wanna see this to the end. So BP if you are listening you might want to think twice about offering 10 dollars . It could cost you more than you think…
I’m not sure where 10 keeps coming from, maybe he has a ton of shares like some and 10 will easily make him a multi millionaire and he just wants to play it safe and cash out. Don’t blame that mindset for many.
The company has had a bumpy road and a lot of mistakes were made along the way which makes 10 sound like a dream to some at this point. A lot was self inflicted but other mistakes were legitimately road blocks from the FDA and possibly BP. If you think it was all self inflicted or not it doesn’t matter the truth is things went slower than anticipated and covid fell flat.
However, it wasn’t too long ago when we were trading at 10 and people where talking about only selling some at 50 and riding the rest for triple digits. Yes triple digits. That’s actually not that unrealistic if we make it and see several approvals over the next 5-10 years.
So when I hear 10 dollars it makes me think of a few things. First people have their individual financial reasons to sell and they change often with time. I won’t get into that but pretty straight forward.
The second thing is, I believe it’s possible that whoever is interested in buying us, if that’s the case, would greatly benefit convincing share holders to sell at 10.
Right ? Because that would be the equivalent of buying something that was 99 precent on sale. So yes I’d be campaigning for 10 all day.
I know nobody asked but since we are on the subject…. I don’t have a single share for sale right now for 10 dollars. Now that doesn’t mean I won’t sell a single share on the way up at 10 this time. If anything it would only be a few thousand shares to say I didn’t miss out like last time and also finally pocket some cash. It would also be the financially smart thing for me to do. That’s why they call it individual financials . Everyone’s different.
So yes 10 imo is a joke. This is also why I do not see a buyout coming. We are too expensive already. Who’s going to pay say 30 billion for a stock that’s trading with a 800 million dollar market cap ? I mean it’s possible but I don’t see it ? Prove me wrong and offer us 50 then we can talk but I don’t see it.
Way too many possible indications. This isn’t a one trick show. The share price could actually be well over 100 dollars in 10 years yet people want to sell at 10?! What ?!
This is why I believe a partner would be best or maybe some other share for share swap so we can watch Leronlimab grow. We have very loyal share holders that wanna see this to the end. So BP if you are listening you might want to think twice about offering 10 dollars . It could cost you more than you think…
(25)
(0)
Daniel Rizzo
Federal Whistleblower
Case Numbers:
HHS & SEC Whistleblower: HL-1412396
DOJ Investigation Report/ Whistleblower ID: 20250705-0001
NIH Case Reference: CS1137565
DOD Case #16282
IC IG / 50 U.S.C. §3033
ARPA-H (Advanced Research Projects Agency for Health)
Founder & CEO of FireGate Bioscience
USPTO: Inventor of the HIV Cure Protocol
[/img]https://investorshangout.com/images/MYImages/1472647104_IMG_3103.png[/img]
https://investorshangout.com/images/MYImages/...G_2859.png
⸻
Public Links
FireGate Bioscience: https://www.firegatebioscience.com
NotYourDrug.com: https://www.notyourdrug.com
https://investorshangout.com/images/MYImages/..._3106.jpeg
https://investorshangout.com/images/MYImages/..._3107.jpeg
The underlying data is protected under federal law specifically 42 U.S.C. § 289b and its implementing regulation, 42 C.F.R. Part 93 through the Office of Research Integrity (askORI) within HHS, and coordinated with the Office of the Secretary / Office of Public Health and Science (OS/OPHS).
- Waiting…
whistleblower_complaints@wyden.senate.gov belongs to Senator Ron Wyden, a senior Democratic U.S. Senator from Oregon.
We are watching YOU……
“This isn’t conspiracy, this is criminal suppression.” - Ohm
https://www.justice.gov/usao-sdny/pr/us-attor...r-programs
https://investorshangout.com/images/MYImages/..._3015.jpeg
???? What Leronlimab Does
• Target: CCR5 receptor (the same receptor people with the CCR5Δ32 mutation lack — like the “Berlin” and “London” patients who were cured after stem cell transplants).
• Effect: By binding CCR5, leronlimab blocks HIV entry into CD4 cells.
• Trial Data:
• In combination therapy trials, ~81% of patients achieved viral loads <50 copies/mL (suppression, not cure).
• As monotherapy, some patients maintained suppression for long stretches (months), but not universally.
⸻
???? Why It Might Be Seen as a “Cure”
• In theory, if you completely block CCR5 on all relevant cells, HIV can’t infect new cells.
• If existing infected reservoirs naturally decay without replenishment, the virus could eventually vanish.
• That’s exactly what happened in the Berlin/London patients — except through stem cell transplants with CCR5Δ32 donors, not a drug.
⸻
???? Why It Hasn’t Been Called a Cure (Yet)
1. HIV Reservoirs Persist
Leronlimab blocks new infection, but it doesn’t flush latent virus from cells. Once treatment stops, those reservoirs can reignite infection.
2. CCR5-Independent Pathways
Some HIV strains use CXCR4 or dual-tropism (CCR5 + CXCR4). Leronlimab won’t stop those.
3. Clinical Conservatism
Researchers avoid using the word “cure” unless patients remain off all therapy with no viral rebound for years. Leronlimab hasn’t shown that in trials.
⸻
???? So Could It Alone Cure HIV?
• In select cases (if someone’s virus is purely CCR5-tropic and their reservoirs naturally decay): maybe.
• But in the general population, it’s unlikely as a monotherapy cure. More realistic is using it as part of a cure combo approach…
Covid
That dosing/timeline mismatch wasn’t just a “mistake.” It sabotaged the trial.
• Day 0 & Day 7 dosing + 10-day half-life = patients had strong coverage through Day 14.
• But the FDA chose Day 28 as the evaluation point……. after drug levels had waned.
• That’s not science. That’s setting the bar where the drug was least likely to shine.
Whether by incompetence or intent, the design ensured leronlimab looked weaker than it actually was. That’s sabotage …..and the community knows it.
In 2020–2021, during CytoDyn’s CD12 trial of leronlimab (PRO-140) in severe/critical COVID-19 patients, the company requested FDA approval to amend the trial design. They wanted to allow a higher 3/4 dosage regimen (because internal data suggested more frequent dosing might improve receptor occupancy and outcomes).
• NP (Nader Pourhassan, then CEO) and Jay Lalezari (Chief Medical Officer) both pushed for that adjustment.
• The FDA denied the request, keeping the protocol locked to the original dosing schedule.
• CytoDyn argued this limited the drug’s chance to demonstrate full efficacy in later-stage COVID patients.
• After the denial, NP frequently mentioned in calls and press releases that the FDA had “handcuffed” the trial design by not allowing higher or adjusted dosing.
So yes….the pushback happened, but the FDA didn’t authorize the dose modification. That denial became one of the sticking points investors and whistleblowers have flagged ever since.
Federal Whistleblower
Case Numbers:
HHS & SEC Whistleblower: HL-1412396
DOJ Investigation Report/ Whistleblower ID: 20250705-0001
NIH Case Reference: CS1137565
DOD Case #16282
IC IG / 50 U.S.C. §3033
ARPA-H (Advanced Research Projects Agency for Health)
Founder & CEO of FireGate Bioscience
USPTO: Inventor of the HIV Cure Protocol
[/img]https://investorshangout.com/images/MYImages/1472647104_IMG_3103.png[/img]
https://investorshangout.com/images/MYImages/...G_2859.png
⸻
Public Links
FireGate Bioscience: https://www.firegatebioscience.com
NotYourDrug.com: https://www.notyourdrug.com
https://investorshangout.com/images/MYImages/..._3106.jpeg
https://investorshangout.com/images/MYImages/..._3107.jpeg
The underlying data is protected under federal law specifically 42 U.S.C. § 289b and its implementing regulation, 42 C.F.R. Part 93 through the Office of Research Integrity (askORI) within HHS, and coordinated with the Office of the Secretary / Office of Public Health and Science (OS/OPHS).
- Waiting… whistleblower_complaints@wyden.senate.gov belongs to Senator Ron Wyden, a senior Democratic U.S. Senator from Oregon.
We are watching YOU……
“This isn’t conspiracy, this is criminal suppression.” - Ohm
https://www.justice.gov/usao-sdny/pr/us-attor...r-programs
https://investorshangout.com/images/MYImages/..._3015.jpeg
???? What Leronlimab Does
• Target: CCR5 receptor (the same receptor people with the CCR5Δ32 mutation lack — like the “Berlin” and “London” patients who were cured after stem cell transplants).
• Effect: By binding CCR5, leronlimab blocks HIV entry into CD4 cells.
• Trial Data:
• In combination therapy trials, ~81% of patients achieved viral loads <50 copies/mL (suppression, not cure).
• As monotherapy, some patients maintained suppression for long stretches (months), but not universally.
⸻
???? Why It Might Be Seen as a “Cure”
• In theory, if you completely block CCR5 on all relevant cells, HIV can’t infect new cells.
• If existing infected reservoirs naturally decay without replenishment, the virus could eventually vanish.
• That’s exactly what happened in the Berlin/London patients — except through stem cell transplants with CCR5Δ32 donors, not a drug.
⸻
???? Why It Hasn’t Been Called a Cure (Yet)
1. HIV Reservoirs Persist
Leronlimab blocks new infection, but it doesn’t flush latent virus from cells. Once treatment stops, those reservoirs can reignite infection.
2. CCR5-Independent Pathways
Some HIV strains use CXCR4 or dual-tropism (CCR5 + CXCR4). Leronlimab won’t stop those.
3. Clinical Conservatism
Researchers avoid using the word “cure” unless patients remain off all therapy with no viral rebound for years. Leronlimab hasn’t shown that in trials.
⸻
???? So Could It Alone Cure HIV?
• In select cases (if someone’s virus is purely CCR5-tropic and their reservoirs naturally decay): maybe.
• But in the general population, it’s unlikely as a monotherapy cure. More realistic is using it as part of a cure combo approach…
Covid
That dosing/timeline mismatch wasn’t just a “mistake.” It sabotaged the trial.
• Day 0 & Day 7 dosing + 10-day half-life = patients had strong coverage through Day 14.
• But the FDA chose Day 28 as the evaluation point……. after drug levels had waned.
• That’s not science. That’s setting the bar where the drug was least likely to shine.
Whether by incompetence or intent, the design ensured leronlimab looked weaker than it actually was. That’s sabotage …..and the community knows it.
In 2020–2021, during CytoDyn’s CD12 trial of leronlimab (PRO-140) in severe/critical COVID-19 patients, the company requested FDA approval to amend the trial design. They wanted to allow a higher 3/4 dosage regimen (because internal data suggested more frequent dosing might improve receptor occupancy and outcomes).
• NP (Nader Pourhassan, then CEO) and Jay Lalezari (Chief Medical Officer) both pushed for that adjustment.
• The FDA denied the request, keeping the protocol locked to the original dosing schedule.
• CytoDyn argued this limited the drug’s chance to demonstrate full efficacy in later-stage COVID patients.
• After the denial, NP frequently mentioned in calls and press releases that the FDA had “handcuffed” the trial design by not allowing higher or adjusted dosing.
So yes….the pushback happened, but the FDA didn’t authorize the dose modification. That denial became one of the sticking points investors and whistleblowers have flagged ever since.
